Market Overview:
The global human growth hormone (HGH) market is expected to grow at a CAGR of 6.5% during the forecast period from 2018 to 2030. The market is segmented on the basis of type, application, and region. On the basis of type, the market is segmented into powder and solvent. The powder segment dominates the global HGH market with a share of more than 60%. This can be attributed to factors such as ease of use and low cost as compared to solvent-based HGH products. On the basis of application, GHD accounts for a majority share in terms of revenue in 2017; however, other applications are expected to witness higher growth rates during the forecast period owing to increasing awareness about benefits associated with HGH therapy among patients suffering from various medical conditions.
Product Definition:
Human Growth Hormone is a protein hormone that is produced by the pituitary gland. It stimulates growth and cell reproduction in humans.
Powder:
Powder is a form of GH (Growth Hormone) that is extracted from the pituitary glands of cattle. It was first developed in the early 20th century and has been used ever since for treating children who failed to grow properly.
Solvent:
Solvent is basically any liquid that can be used to dissolve another substance. In the case of GH, the substance being dissolved is insulin. The most common types of solvents are water and alcohol.
Alcohol as a solvent has been around since ancient times.
Application Insights:
The others segment includes acromegaly, Cushing¢â‚¬â„¢s disease and pituitary tumor. The application of human growth hormone for the treatment of acromegaly is under active investigation. However, the approval for this use in any region is expected to be delayed due to lack of awareness and availability of effective treatment alternatives such as somatropin analogs that are FDA approved for clinical use.
Growth hormone deficiency (GHD) held a significant share in 2017 owing to increasing prevalence coupled with high unmet medical needs associated with short stature and obesity among children as well as adults globally. According to data published by the WHO, approximately 90% of patients diagnosed with GHD fall into one or more sub-groups based on age: pediatric GH deficiency (PEGH), adult GH deficiency (AGH) and aging-related GH deficiency (DGH).
Regional Analysis:
North America dominated the global market in 2017. The presence of key players, availability of branded formulations, and high awareness levels among patients are some factors responsible for its large share. Moreover, an increase in R&D activities to develop novel drugs is expected to drive the growth over the forecast period.
Asia Pacific is anticipated to witness lucrative growth during the forecast period owing to rising disposable income and improving healthcare infrastructure in emerging countries such as China and India. Furthermore, an increase in prevalence of GHD coupled with growing awareness about available treatment options will support regional market expansion over the next eight years.
Growth Factors:
- Increasing awareness about the benefits of Human Growth Hormone therapy among people.
- Growing geriatric population who are more susceptible to various growth hormone deficiencies.
- Rising prevalence of lifestyle diseases such as obesity and diabetes which can lead to growth hormone deficiency.
- increasing investment by pharmaceutical companies in research and development for new human growth hormone therapies .
Scope Of The Report
Report Attributes
Report Details
Report Title
Human Growth Hormone Market Research Report
By Type
Powder, Solvent
By Application
Growth Hormone Deficiency (GHD), Turner Syndrome, Chronic Renal Insufficiency, Prader Willi Syndrome, Small for Gestational Age, SHOX Deficiency, Others
By Companies
Novo Nordisk, Pfizer, Eli Lilly, Merck Serono, F. Hoffmann-La Roche, Ferring Pharmaceuticals, GeneScience Pharmaceuticals, Ipsen, LG Life Sciences, Sandoz International, Anhui Anke Biotechnology
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
249
Number of Tables & Figures
175
Customization Available
Yes, the report can be customized as per your need.
Global Human Growth Hormone Market Report Segments:
The global Human Growth Hormone market is segmented on the basis of:
Types
Powder, Solvent
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Growth Hormone Deficiency (GHD), Turner Syndrome, Chronic Renal Insufficiency, Prader Willi Syndrome, Small for Gestational Age, SHOX Deficiency, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Novo Nordisk
- Pfizer
- Eli Lilly
- Merck Serono
- F. Hoffmann-La Roche
- Ferring Pharmaceuticals
- GeneScience Pharmaceuticals
- Ipsen
- LG Life Sciences
- Sandoz International
- Anhui Anke Biotechnology
Highlights of The Human Growth Hormone Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Powder
- Solvent
- By Application:
- Growth Hormone Deficiency (GHD)
- Turner Syndrome
- Chronic Renal Insufficiency
- Prader Willi Syndrome
- Small for Gestational Age
- SHOX Deficiency
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Human Growth Hormone Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Human growth hormone (HGH) is a peptide hormone that stimulates the body's natural production of growth hormones. HGH has been shown to help improve muscle mass, strength, and endurance; reduce fat storage; and increase bone density.
Some of the major players in the human growth hormone market are Novo Nordisk, Pfizer, Eli Lilly, Merck Serono, F. Hoffmann-La Roche, Ferring Pharmaceuticals, GeneScience Pharmaceuticals, Ipsen, LG Life Sciences, Sandoz International, Anhui Anke Biotechnology.
The human growth hormone market is expected to register a CAGR of 6.5%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Human Growth Hormone Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Human Growth Hormone Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Human Growth Hormone Market - Supply Chain
4.5. Global Human Growth Hormone Market Forecast
4.5.1. Human Growth Hormone Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Human Growth Hormone Market Size (000 Units) and Y-o-Y Growth
4.5.3. Human Growth Hormone Market Absolute $ Opportunity
5. Global Human Growth Hormone Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Human Growth Hormone Market Size and Volume Forecast by Type
5.3.1. Powder
5.3.2. Solvent
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Human Growth Hormone Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Human Growth Hormone Market Size and Volume Forecast by Application
6.3.1. Growth Hormone Deficiency (GHD)
6.3.2. Turner Syndrome
6.3.3. Chronic Renal Insufficiency
6.3.4. Prader Willi Syndrome
6.3.5. Small for Gestational Age
6.3.6. SHOX Deficiency
6.3.7. Others
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Human Growth Hormone Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Human Growth Hormone Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Human Growth Hormone Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Human Growth Hormone Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Human Growth Hormone Demand Share Forecast, 2019-2026
9. North America Human Growth Hormone Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Human Growth Hormone Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Human Growth Hormone Market Size and Volume Forecast by Application
9.4.1. Growth Hormone Deficiency (GHD)
9.4.2. Turner Syndrome
9.4.3. Chronic Renal Insufficiency
9.4.4. Prader Willi Syndrome
9.4.5. Small for Gestational Age
9.4.6. SHOX Deficiency
9.4.7. Others
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Human Growth Hormone Market Size and Volume Forecast by Type
9.7.1. Powder
9.7.2. Solvent
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Human Growth Hormone Demand Share Forecast, 2019-2026
10. Latin America Human Growth Hormone Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Human Growth Hormone Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Human Growth Hormone Market Size and Volume Forecast by Application
10.4.1. Growth Hormone Deficiency (GHD)
10.4.2. Turner Syndrome
10.4.3. Chronic Renal Insufficiency
10.4.4. Prader Willi Syndrome
10.4.5. Small for Gestational Age
10.4.6. SHOX Deficiency
10.4.7. Others
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Human Growth Hormone Market Size and Volume Forecast by Type
10.7.1. Powder
10.7.2. Solvent
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Human Growth Hormone Demand Share Forecast, 2019-2026
11. Europe Human Growth Hormone Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Human Growth Hormone Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Human Growth Hormone Market Size and Volume Forecast by Application
11.4.1. Growth Hormone Deficiency (GHD)
11.4.2. Turner Syndrome
11.4.3. Chronic Renal Insufficiency
11.4.4. Prader Willi Syndrome
11.4.5. Small for Gestational Age
11.4.6. SHOX Deficiency
11.4.7. Others
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Human Growth Hormone Market Size and Volume Forecast by Type
11.7.1. Powder
11.7.2. Solvent
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Human Growth Hormone Demand Share, 2019-2026
12. Asia Pacific Human Growth Hormone Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Human Growth Hormone Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Human Growth Hormone Market Size and Volume Forecast by Application
12.4.1. Growth Hormone Deficiency (GHD)
12.4.2. Turner Syndrome
12.4.3. Chronic Renal Insufficiency
12.4.4. Prader Willi Syndrome
12.4.5. Small for Gestational Age
12.4.6. SHOX Deficiency
12.4.7. Others
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Human Growth Hormone Market Size and Volume Forecast by Type
12.7.1. Powder
12.7.2. Solvent
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Human Growth Hormone Demand Share, 2019-2026
13. Middle East & Africa Human Growth Hormone Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Human Growth Hormone Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Human Growth Hormone Market Size and Volume Forecast by Application
13.4.1. Growth Hormone Deficiency (GHD)
13.4.2. Turner Syndrome
13.4.3. Chronic Renal Insufficiency
13.4.4. Prader Willi Syndrome
13.4.5. Small for Gestational Age
13.4.6. SHOX Deficiency
13.4.7. Others
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Human Growth Hormone Market Size and Volume Forecast by Type
13.7.1. Powder
13.7.2. Solvent
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Human Growth Hormone Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Human Growth Hormone Market: Market Share Analysis
14.2. Human Growth Hormone Distributors and Customers
14.3. Human Growth Hormone Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Novo Nordisk
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Pfizer
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Eli Lilly
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Merck Serono
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. F. Hoffmann-La Roche
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Ferring Pharmaceuticals
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. GeneScience Pharmaceuticals
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. Ipsen
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. LG Life Sciences
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. Sandoz International
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. Anhui Anke Biotechnology
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. COMPANY 12
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
